

**BOOK BEFORE AUGUST 24TH  
AND SAVE UP TO \$900**

**December 4 – 6 | Boston, MA**  
[www.oncolyticvirotherapies.com](http://www.oncolyticvirotherapies.com)

4th Annual  
**ONCOLYTIC  
VIROTHERAPY**  
Summit



- **Innovate Novel Payloads and Delivery Technologies**
- **Exclusive Clinical Updates on Combination Therapies**
- **Future Proof Strategies to Advance Oncolytic Viruses**



**Expert Speakers Include:**



**Robert Coffin**  
Chief Executive Officer  
**Replimune**



**Magnus Jaderberg**  
Chief Medical Officer  
**Targovax**



**Min Liang**  
Chief Scientific Officer  
**TOT Biopharm**



**Brad Nelson**  
Director, Deeley Research  
Centre  
**BC Cancer Agency**



**Rachel Altura**  
Senior Medical Director  
**Merck & Co.**



**Anna Cascante**  
Head of R&D  
**Sagettis Biotech**



**Antonio Chiocca**  
Professor of Neurosurgery  
**Harvard Medical School**



**José Manuel Otero**  
Vice President, CMC &  
Manufacturing  
**Turnstone Biologics**



**William Jia**  
Chief Scientific Officer  
**Virogin**

## Supercharge your Oncology Combinations with Oncolytic Virus Immunotherapies

The 4th Annual Oncolytic Virotherapy Summit continues to be the industry leading forum dedicated exclusively to advancing clinically and commercially successful oncolytic viruses

The 4th Oncolytic Virotherapy Summit is the leading resource for biotech and pharma drug developers to gain scientific and clinical trial updates, discuss current challenges and network with senior leaders in the oncolytic virotherapy field.

With a case-study led agenda and a technical focus on novel combination OV approaches, such as **CAR-T**, **immune checkpoint inhibitors** and **current standard of care**, join the thought leaders as we find the most fitting niche for OVs in the immuno-oncology space.

The OV Summit 2018 will guide you through the **global regulatory landscape**, optimize **manufacturing platforms** and boost **investment** in the field.

Learn, network and interact with your colleagues in the oncolytic virotherapy field to shape the future of oncology combinations and enhance the continued growth of oncolytic virotherapies.

What previous Oncolytic Virotherapy Summit attendees have to say:

“The Oncolytic Virotherapy Summit is an awesome opportunity to network, to learn what has been happening in the OV field and also what to expect in the future”

Past Attendee from Boehringer Ingelheim

“Excellent meeting with substantive content”

Past Attendee from Tocagen Inc.

### What to Expect

 **100+**  
Attendees


 **8+**  
Hours of  
Networking

## Your Checklist to Accelerate the Clinical Development of Your Oncolytic Immunotherapy

1.

**Enhance the Anti-Tumoral Activity of your Virus with Transgenes.**

Examine approaches and results from **Robert Coffin, CEO of Replimmune** and **Stephen Thorne, CSO of Western Oncolytics**



2.

**Assess the Best Combination Approaches**

Hear clinical trial results of combinations with chemotherapy and checkpoint inhibitors from **Merck** and **Targovax**



3.

**Discover if OVs can be Leveraged to enhance CAR-T?**

Identify how solid tumors can be tackled using oncolytic viruses in combination with CAR T-cell therapy, with insights from **Baylor College of Medicine** and **BC Cancer Agency**



4.

**Expand the global reach of your oncolytic virotherapy**

Learn how Oncorine was approved in China from the **former CSO of Shanghai Sunway Biotech**




5.

**Maximize the efficiency and minimize the cost of manufacturing**

See key manufacturing strategies taken by **Turnstone** and discuss about the choosing the best contract manufacturers and bringing manufacturing in-house.



# YOUR EXPERT SPEAKERS



**Grant McFadden**  
Center Director  
& Professor,  
Biodesign Center for  
Immunotherapy  
**Arizona State  
University**



**Masataka Suzuki**  
Assistant Professor  
**Baylor College of  
Medicine**



**Brad Nelson**  
Director, Deeley  
Research Centre  
**BC Cancer Agency**



**Frank Tufaro**  
Chief Executive  
Officer  
**DNatrix**



**Antonio Chiocca**  
Professor of  
Neurosurgery  
**Harvard Medical  
School**



**Faris Farassati**  
Director of Molecular  
Medicine Laboratory  
**Kansas City  
Veteran Affairs  
Medical Center**



**Angelica Loskog**  
Chief Executive  
Officer  
**Lokon Pharma**



**Rachel Altura**  
Senior Medical  
Director  
**Merck & Co.**



**Christophe Queva**  
Chief Scientific  
Officer  
**Oncorus**



**Steven Potts**  
Chief Executive  
Officer  
**OncoMyx**



**Robert Coffin**  
Chief Executive  
Officer  
**Replimune**



**Anna Cascante**  
Head of R&D  
**Sagettis Biotech**



**Magnus Jaderberg**  
Chief Medical  
Officer  
**Targovax**



**Min Liang**  
Chief Scientific  
Officer  
**TOT Biopharm**



**José Manuel Otero**  
Vice President, CMC  
& Manufacturing  
**Turnstone Biologics**



**Daniel Katzman**  
Chief Executive  
Officer  
**Unleash Immuno  
Oncolytics**



**Stephen Thorne**  
Chief Scientific  
Officer  
**Western Oncolytics**



**William Jia**  
Chief Scientific  
Officer  
**Virogen**

# CONFERENCE DAY ONE

## WEDNESDAY DECEMBER 5 2018

### 8.45 Chair's Opening Remarks

### Clinical Data Presentations for Oncolytic Virotherapy Combinations



**Frank Tufaro**  
Chief Executive  
Officer  
**DNatrix**

#### 9.00 Combination with Checkpoint Inhibitors: The Path to Commercial Success?

- How can OV be leverage in combination with immune checkpoint inhibitors
- Dosing, Timing and payer strategy associated
- The best design of experiments that is also not too expensive to run



**Magnus Jaderberg**  
Chief Medical Officer  
**Targovax**

#### 9.30 ONCOS-102 Data as Monotherapy & Combination with CPI & Chemo

- Targovax's lead product candidate, ONCOS-102, is an oncolytic adenovirus that has been genetically engineered to selectively infect, replicate in and destroy cancer cells, and to trigger tumor specific immune responses
- The immune activation potential of ONCOS-102 has been demonstrated in a single-agent phase I trial, as well as in ongoing combination trials with both check-point inhibitors and chemotherapy
- The lead indication for ONCOS-102 is mesothelioma where its efficacy is currently being assessed in combination with chemotherapy in a randomized phase II trial. ONCOS-102 is also being tested in advanced melanoma, where important proof of concept data in checkpoint inhibitor refractory patients is currently being produced



**Rachel Altura**  
Senior Medical  
Director  
**Merck & Co**

#### 10.00 Effective Combination Therapies Between Different Viruses and Drug Strategies to Maximise Efficacy

- Combinations that are already in the clinic or under investigation
- Molecular targeted drugs, chemotherapy and radiation therapy
- Clinical trial results of non-immune based strategies

### 10.30 Morning Refreshments and Speed Networking



**Robert Coffin**  
Chief Executive  
Officer  
**Replimune**

#### 11.30 Replimune's Multiple Armed Immunlytic Oncolytic Immuno-Geno-Therapy Platform





- Replimune has developed a new high potency oncolytic immunotherapy platform based on HSV
- These viruses are armed with multiple transgenes to both increase direct tumor killing and to enhance the systemic anti-tumor immune response
- The most advanced product candidate, RP1, is currently in clinical development for several tumor types, in combination with PD1 blockade
- RP2, which additionally expresses an anti-CTLA-4 antibody, is scheduled to enter clinical development in the first of half of 2019



**Angelica Loskog**  
Chief Executive  
Officer  
**Lokon Pharma**

#### 12.00 Effective Combination Therapies to Maximise Immune Response to Improve Current Stand of Care

- LOAd703 is an oncolytic immunostimulatory adenovirus with two transgenes: TMZ-CD40L and 4-1BBL
- LOAd703 potently activates DCs to stimulate both T cell and NK cell responses
- LOAd703 is under clinical investigation as an add-on treatment to chemotherapy for patients with pancreatic-, biliary-, colorectal-, and ovarian cancer.

<b>12.30 Lunch and Networking</b>	
<b>Discovery Considerations for Next Generation Oncolytic Viruses</b>	
 <b>William Jia</b> Chief Scientific Officer <b>Virogin</b>   <b>Robert Coffin</b> Chief Executive Officer <b>Replimune</b>	<p><b>13.30 Panel Discussion: Comparing and Contrasting Virus Types</b></p> <ul style="list-style-type: none"> <li>• Compare and contrast wild-type and newer generations expressing immune stimulatory payloads or tumor antigens</li> <li>• Selecting oncolytic backbone that are strong immune stimulators to increase virus potency</li> <li>• Understand why some strains are better than others for generating anti-tumor activity</li> </ul>
 <b>Antonio Chiocca</b> Professor of Neurosurgery <b>Harvard Medical School</b>	<p><b>14.30 Mechanism of Action for Killing Tumors to Demonstrate Successful Activity</b></p> <ul style="list-style-type: none"> <li>• Determining the presence of antiviral response and antitumoral response</li> <li>• Determining the action of myeloid cells in the tumor microenvironment</li> </ul>
 <b>Faris Farassati</b> Director of Molecular Medicine Laboratory <b>Kansas City Veteran Affairs Medical Center</b>	<p><b>15.00 Pro-oncogenic Cell Signalling Pathways as a Platform for Development of Novel Oncolytic Viruses</b></p> <ul style="list-style-type: none"> <li>• Expanding understanding of cell signaling pathways that control malignancies</li> <li>• Opportunity to design novel generations of oncolytic viruses with enhanced efficiency and reduced toxicity.</li> <li>• Review some possibilities in this regards with a special focus on merging the two fields of molecular oncology and oncolytic virotherapy.</li> </ul>
<b>15.30 Afternoon Break &amp; Scientific Poster Session</b>	

**16.00 Roundtable Discussion**

More practical and highly interactive breakout roundtables where attendees can crowd-source solutions and share opinions around pre-assigned topic areas. A valuable chance for attendees to unite around hot topics and debate best practice. No more sitting quietly, this is a dedicated opportunity for you to voice your experiences and identify unique solutions.

 <b>1</b>  <b>Assessing the Advantages and Limitations of Various Preclinical Models for Better Translation</b>	<b>2</b>  <b>Innovating Clinical Trial Design to Improve Efficiency and Reduce Cost</b>	<b>3</b>  <b>Choosing Indications that Allow Leveraging of Oncolytic Viruses to Successfully Compete with Other Therapies</b>
---	---	---

<b>17.00 Chair's Closing Remarks</b>	
<b>17.15 End of Day 1</b>	

# CONFERENCE DAY TWO

## THURSDAY DECEMBER 6 2018

### 8.45 Chair's Opening Remarks

### Discovery Considerations for Monotherapies and Combination Therapies



**Grant McFadden**  
Center Director  
& Professor,  
Biodesign Center for  
Immunotherapy  
**Arizona State  
University**

#### 9.00 Ex vivo Virotherapy with Myxoma Virus

- Myxoma virus is an oncolytic poxvirus with tropism for a wide variety of cancer cells
- Immunostimulatory transgenes expressed from myxoma virus can improve anti-tumor responses
- Leveraging myxoma's unique immunostimulatory properties in hematologic malignancies



**Masataka Suzuki**  
Assistant Professor  
**Baylor College of  
Medicine**

#### 9.30 Oncolytic Adenoimmunotherapy Partners CAR T-cell Therapy for Solid Tumor Treatment

- Local treatment of oncolytic adenovirus is safe but is insufficient to eradicate advanced/metastasized tumors.
- Successful CAR T-cell therapy for solid tumors needs to overcome multiple barriers.
- Combination with oncolytic adenovirus and CAR T-cell overcomes the inherent limitations of each agent.



**Christophe Queva**  
Chief Scientific  
Officer  
**Oncorus**

#### 10.00 Novel Micro-RNA Attenuated Oncolytic HSV Virus with Combinatorial Immune Payloads for the Treatment of Metastatic Cancer

- Oncorus is developing the next generation HSV-based oncolytic virus with enhanced potency for tumor cell killing and recruitment of the immune system.
- Oncorus' innovative miR-attenuation strategy enables robust viral replication in tumor cells, while preventing replication in healthy tissue.
- Oncorus' oHSV are armed with multiple immunomodulatory payloads to synergistically increase recruitment and effector function of immune cells, thus harnessing the full potential of OV's to evoke an abscopal immune response.

### 10.30 Morning Refreshments & Networking

### Novel Effective Delivery Technologies



**William Jia**  
Chief Scientific  
Officer  
**Virogin**

#### 11.00 Strategies for Enhancing Efficacy of Oncolytic Virotherapy

- An IND enabled OV---VG161 armed with multiple immune regulatory factors for better anti-tumor efficacy
- Virogin's next generation of OV with transcriptional and translational dual control for i.v. deliverables
- Strategies to enhance OV intratumoral replication by targeting tumor associated nontumor cells



**Steven Potts**  
Chief Executive  
Officer  
**OncoMyx**

#### 11.30 OncoMyx Therapeutics: Targeting Hematologic & Solid Tumors with Systemic Delivery

- Delivery of virus to disseminated cancer can be increased by infusion of ex vivo myxoma-infected leukocytes
- Clinical development of a novel systemic delivery system using leukocyte transported virus



**Anna Cascante**  
Head of R&D  
**Sagetis Biotech**

#### 12.00 Virosshield™ : An Innovative Polymeric Coating Technology to Enable Systemic Delivery of Oncolytic Viruses

- Biodistribution changes that lead to increased viral payloads in the tumor.
- Electrostatic interaction between the polymer and the virus that doesn't hinder its infectivity.
- Protection against adaptive immune response leading to an improved efficacy in presence of neutralizing antibodies.
- Universal system applicable to different types of viruses.

**12.10 Lunch and Networking**

**Improving Manufacturing to Minimize Time & Cost**

  
**Christophe Queva**  
Chief Scientific  
Officer  
**Oncorus**

  
**Frank Tufaro**  
Chief Executive  
Officer  
**DNatrix**

  
**Magnus Jaderberg**  
Chief Medical Officer  
**Targovax**


**13.00 Panel Discussion: Selecting the Best Contract Manufacturing to Ensure Quality Product**

- Criterias for selection based on expertise, turn around time and cost
- Improving trust, build relationships and clarity around communications
- Protecting your intellectual property

  
**Min Liang**  
Chief Scientific  
Officer  
**TOT Biopharm**

**14.00 R&D, Clinical Development & GMP Manufacturing of Oncolytic Viruses in China**

- Oncorine - the first oncolytic virotherapy product, lessons learned from it.
- A new state-of-the-art oncolytic virus GMP manufacture platform.
- Regulatory considerations of oncolytic viruses in China.



  
**José Manuel Otero**  
Vice President, CMC  
& Manufacturing  
**Turnstone Biologics**

**14.30 CMC Development Strategies for Viral Immunotherapeutics: Keeping the End in Mind**

- Live-virus immunotherapeutics are accelerating in their development, with bioprocess development and manufacturing as key enablers. Strategy selection early in pre-clinical and clinical development is critical to impacting late-stage commercialization efforts.
- Oncolytic viruses while still a relatively new product class, with limited commercial success stories, benefit heavily from the broader live-virus vaccine development experience, and must be responsive to new regulatory expectations.
- CMC competency and capabilities are not only enablers of product development, but can be a key differentiator and advantage as the field continues to mature/grow.

**15.00 Chair's Closing Remarks**

**15.15 End of Day 2**

 The Oncolytic Virotherapy Summit is an awesome opportunity to network, to learn what has been happening in the OV field and also what to expect in the future 

**Past Attendee from Boehringer Ingelheim**

# PRE-CONFERENCE WORKSHOP DAY TUESDAY DECEMBER 4 2018

## Workshop A

### Establishing Collaborations & Bringing Investments in the OV Space

9:00 - 12:00

As large pharmas and venture capitalists are looking to invest in the advancing oncolytic virotherapy space, it is important to understand multiple points of views to strategize future research and developments. In this workshop, we bring together pharmas, biotechs and investors to have an in-depth dialogue on novel opportunities in the field.

**Attendees will discuss in detail:**

- How large pharma see OV as a part of the oncology portfolio
- What results do investors need to see to convince them of the potential?
- Strategies in collaboration and external partnerships



**Workshop Leader**  
**Rachel Altura**  
Senior Medical Director  
**Merck & Co.**

Rachel Altura, M.D. is Senior Medical Director in Early Oncology Development at Merck & Co in Rahway, NJ USA and Adjunct Associate Professor at the Alpert Medical School at Brown University in Providence, RI USA. She oversees several global Phase 1/2 clinical trials in immuno-oncology. Prior to this role, she was an Associate Professor in the Department of Pediatrics at Brown University and physician scientist with a laboratory focus on translational oncology and clinical focus on pediatric oncology.

## Workshop B

### Selecting & Optimizing Therapeutic Transgenes for Oncolytic Viruses

13:00 - 16:00

Leveraging oncolytic viruses to elicit the right immune response has been determined as the key for the field. Understanding the key to selecting and optimizing viruses could determine the success of the virus in the clinic.

**Attendees will discuss in detail:**

- Selection criteria for therapeutic transgenes; oncolytic viruses are different to gene therapy
- Combining multiple therapeutic transgenes into a single vector.
- Important additional considerations; promoters, modifications, genome locations etc.



**Workshop Leader**  
**Stephen Thorne**  
Chief Scientific Officer  
**Western Oncolytics**

Stephen Thorne trained at Oxford University and Imperial College, London with additional post-doctoral experience at Cancer Research UK and Stanford University. He also helped found Jennerex biotherapeutics. While working as an Assistant Professor at the University of Pittsburgh his lab developed the technology that has been licensed by Western Oncolytics. He is currently CSO at Western Oncolytics.



# PARTNERSHIP OPPORTUNITIES


In recent years, the oncolytic virotherapy field has seen a lot of injections of investments. Drug developers are now on the look-out for the most innovative service providers involved in preclinical animal modelling, regulatory and CMC consulting, clinical development and contract manufacturing.

This is the perfect opportunity to demonstrate your technology, expertise and capacity to meet the increasing demands of this emerging field.


## Tailored Opportunities include:

- Speaking Opportunities** – position yourself as the thought leader in your space and educate the market
  - Panel Moderator** – curate and drive the conversation alongside leaders of the field
  - Roundtable Leader** – interact intimately with your market audience to understand their needs
  - Workshop Leader** – lead a focused and in-depth discussion with a targeted audience
  - Exclusive VIP Hosting** – build or cement relationships through informal channels
  - Exhibition Stand** – have your flag in the ground and showcase your technology to the onsite community of senior decision makers
- For further information, contact Jennifer Mackay (details below).

## TYPICAL ATTENDANCE SENIORITY



## ESTIMATED ATTENDANCE BY SECTOR



\*Based on market research and previous events' statistics

## PAST DELEGATES INCLUDE:



## PAST PARTNERS INCLUDE



**BECOME A  
COMMERCIAL PARTNER**



**Jennifer Mackay**  
Senior Partnership Director  
Tel: +1 617 455 4188  
Email: [sponsor@hansonwade.com](mailto:sponsor@hansonwade.com)

# READY TO REGISTER?

## 3 EASY WAYS TO BOOK



[www.oncolyticvirotherapies.com/register](http://www.oncolyticvirotherapies.com/register)



Tel: +1 617 455 4188



Email: [register@hansonwade.com](mailto:register@hansonwade.com)

**REGISTER  
BY AUGUST  
24TH AND  
SAVE UP TO  
\$900**

### Team Discounts\*

- 10% discount – 3 delegates
- 15% discount – 4 delegates
- 20% discount – 5 or more

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

## SECURE YOUR PLACE

Drug Developers (Pharma & Biotech)	Register Before August 24th (SAVE \$900)
Conference + 2 Workshops	\$2,897
Conference + 1 Workshop	\$2,398
Conference Only	\$1,899
Workshops (each)	\$599
Academic Institutions	Register Before August 24th (SAVE \$600)
Conference + 2 Workshops	\$1,797
Conference + 1 Workshop	\$1,398
Conference Only	\$999
Workshops (each)	\$499
Solution Providers	Register Before August 24th (SAVE \$700)
Conference + 2 Workshops	\$3,597
Conference + 1 Workshop	\$2,998
Conference Only	\$2,399
Workshops (each)	\$699



## VENUE

**Hilton Boston Back Bay Hotel**  
40 Dalton St, Boston  
MA 02115, USA

For further information or assistance, please visit  
[www.hilton.com/en/hotels/massachusetts/hilton-boston-back-bay-BOSBHHH/index.html](http://www.hilton.com/en/hotels/massachusetts/hilton-boston-back-bay-BOSBHHH/index.html)

### TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, 52 Grosvenor Gardens, Belgravia, London SW1W 0AU